Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Ads

You May Also Like

Curetis Publishes Interim Report for the First Half-Year 2018

Curetis Publishes Interim Report for the First Half-Year 2018 Amsterdam, the Netherlands, San Diego, ...

HTG Molecular Diagnostics Reports Second Quarter 2018 Results

Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in ...